stockrowCelldex Therapeutics, Inc.
CLDX Healthcare Biotechnology
Celldex Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.5 million, down 78.0% from fiscal 2024.
- Revenue
- −96.8%
- EPS
- −10.6%
- Free cash flow
- −35.5%
Quarter to June 2026, against a year earlier
Follow CLDX
Alert me
Celldex Therapeutics, Inc. (CLDX) EBITDA
Celldex Therapeutics, Inc.'s EBITDA for fiscal 2025 was −$289.8M, compared with −$207.7M in fiscal 2024. Over the twelve months to 30 June 2026 it was −$326.7M. Over the past ten years it has ranged from −$289.8M (fiscal 2025) to −$42.2M (fiscal 2020) — the current reading is the lowest in ten years. EBITDA has fallen for 5 consecutive fiscal years. Celldex Therapeutics, Inc. ranks 555th of 594 Biotechnology companies by EBITDA.
EBITDA, annual
Embed this chart
Annual newest first
| Period | EBITDA | Change |
|---|---|---|
| FY2025 | −$289.8M | — |
| FY2024 | −$207.7M | — |
| FY2023 | −$157.8M | — |
| FY2022 | −$111.5M | — |
| FY2021 | −$67.9M | — |
| FY2020 | −$42.2M | — |
| FY2019 | −$51.3M | — |
| FY2018 | −$62.7M | — |
| FY2017 | −$116.5M | — |
| FY2016 | −$127.9M | — |
Quarterly newest first
| Period | EBITDA | Change |
|---|---|---|
| Jun 2026 | −$81.4M | — |
| Mar 2026 | −$84.2M | — |
| Dec 2025 | −$87.2M | — |
| Sep 2025 | −$73.8M | — |
| 42 more quarters | Free account |
Against its own ten years
EBITDA against peers
| Company | EBITDA |
|---|---|
| ADMA ADMA Biologics Inc compare | $232.8M |
| AUPH Aurinia Pharmaceuticals Inc compare | $163.4M |
| VCEL Vericel Corporation compare | $31.3M |
| PVLA Palvella Therapeutics, Inc. compare | −$57.7M |
| PHVS Pharvaris N.V. compare | −$212.2M |
| IMNM Immunome, Inc. compare | −$268.3M |
| CLDX Celldex Therapeutics, Inc. | −$326.7M |
| VERA Vera Therapeutics, Inc. compare | −$417.0M |
| BHVN Biohaven Ltd. compare | −$515.1M |
What EBITDA is
EBITDA shows what a company earns from its operations before interest, taxes and the non-cash charges for depreciation and amortization.
Reported line item
More on CLDX
- Revenue
- Net income
- EPS (diluted)
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement